Skip to main content

Primary intraocular lens implantation and secondary glaucoma after congenital and infantile cataract surgery: a systematic review of randomized and observational evidence

In brief

Three trials in 228 children leave glaucoma risk after lens implants uncertain

In randomized trials, primary lens implantation showed no clear difference in glaucoma compared with leaving the eye without a lens initially, but the studies were too small to rule out meaningful benefit or harm. Observational studies found lower glaucoma odds with implants, yet confounding and uneven follow-up weaken that signal, so glaucoma prevention alone should not guide the choice.

Journal
Frontiers in medicine (Q1)
Published
5 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Wei Zhang, Beibei Bie, Huanle Fang, Luning Zhang
PMID
43060893
DOI
10.3389/fmed.2026.1985280

Why clinicians should know about it

  • Picked for Ophthalmology (top studies of the week, 22 November 2026): Glaucoma risk informs lens choice in pediatric cataract surgery

Abstract

BACKGROUND: The association between primary intraocular lens (IOL) implantation and glaucoma after congenital or infantile cataract surgery remains uncertain. In this study, we compared randomized and observational evidence to assess glaucoma outcomes after primary IOL implantation vs. initial aphakia. METHODS: Five databases were searched for studies published from January 1999 to 8 August 2026. Randomized trials formed the primary synthesis, taking into account one eye per child; observational cohorts and matched case-control evidence were evaluated separately. Random-effects odds ratios (ORs) were estimated via Paule-Mandel variance estimation and Hartung-Knapp confidence intervals (CIs). The risk of bias and evidence certainty were assessed based on the study design. Exploratory analyses examined baseline comparability, follow-up, and outcome definitions. RESULTS: Twenty-one studies were included: three randomized trials, 17 cohort studies, and one nested case-control study. The trials included 228 children and yielded an OR of 1.01 (95% CI, 0.31-3.24; low-certainty evidence). Fifteen cohort studies with events yielded an unadjusted OR of 0.15 (95% CI, 0.06-0.36; I2 = 73.4%; very-low-certainty evidence). Two additional cohort studies reported no glaucoma events in either group. A five-study analysis combining the trials with observational comparisons selected for greater baseline comparability yielded an OR of 1.09 (95% CI, 0.69-1.74). Confounding by surgical age, ocular anatomy, and treatment selection was a major limitation of the observational evidence. CONCLUSIONS: Randomized evidence remains compatible with clinically important benefit or harm from primary IOL implantation. The lower glaucoma odds observed in cohorts differ from the randomized findings and require interpretation in the context of baseline imbalance and heterogeneous follow-up. Therefore, glaucoma prevention alone is an insufficient basis for selecting primary IOL implantation. SYSTEMATIC REVIEW REGISTRATION: https://osf.io/r86hv/, Identifier: 10.17605/OSF.IO/R86HV.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.